Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sudubrilimab
- Development stage
- Unknown
- Lead developer
- Zhejiang Hisun Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Sudubrilimab (HS636) is a fully human IgG1-kappa monoclonal antibody targeting programmed death-ligand 1 (PD-L1). It acts as a PD-L1 inhibitor and is designed to block the interaction between PD-L1 and its receptor PD-1, thereby enhancing T-cell mediated immune responses against tumor cells. Sudubrilimab is being developed primarily for the treatment of hematologic malignancies and solid tumors. The drug has been evaluated in phase I clinical trials for safety and tolerability in advanced malignant tumors and in phase II trials for relapsed or refractory primary mediastinal large B-cell lymphoma[2][8][9]. The originator organization is Zhejiang Hisun Pharmaceutical.
- Brand names
- sudubrilimab
- Other names
- recombinant anti-PD-L1 human monoclonal antibody重组抗PD-L1全人源单克隆抗体注射液
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on sudubrilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sudubrilimab.